Sigmoidoscopy Screening: Understanding the Trade-off Between Detection of Advanced Neoplasia and Diagnostic Efficiency

Thomas F. Imperiale

Correspondence to: Thomas F. Imperiale, MD, Regenstrief Institute, Inc, 1050 Wishard Blvd, Indianapolis, IN 46202-5121 (e-mail: timperia@iupui.edu).

Sigmoidoscopy may reduce the incidence and mortality of colorectal cancer (CRC) in two ways. The first is by direct detection of distal (left-sided) early-stage CRC and removal of precancerous adenomatous polyps. The second takes advantage of the association between distal neoplastic findings and advanced neoplasia in the proximal colon. Several studies have shown a synchronous relationship between distal neoplastic findings and advanced proximal neoplasia (APN), in which the risk (or prevalence) of APN increases as the extent of distal neoplasia increases (1–4).

Between 2009 and 2012, four trials of screening sigmoidoscopy were published (5–8), three of which reported outcomes of one-time sigmoidoscopy compared with usual care (5–7). Table 1 shows descriptive data and main results of the three trials. The trials are similar in the age range of invited and screened subjects, in intervention and control groups, and in the primary end points (CRC incidence and mortality). In all four trials, the effect of sigmoidoscopy on overall CRC mortality was due to its effect on distal CRC.

Despite their similarities, the trials differ somewhat in their main findings. The differences in cancer outcomes may be due to differences in the underlying populations’ risk profiles, in persons who were willing to participate and who were randomly assigned, in their adherence to the trial, and in follow-up duration (and the shorter duration for the Norwegian Colorectal Cancer Prevention Trial (NORCCAP) trial likely accounts for the lack of effect on screening on CRC incidence). These factors are beyond the control of study investigators and providers. Another reason for the differences in outcomes—one that is controllable—is the intervention itself: how well sigmoidoscopy was performed, and perhaps most important, the sigmoidoscopic findings that led to further evaluation with colonoscopy. Among the three trials, the proportion of patients referred for colonoscopy after sigmoidoscopy ranged from 4% in the Screening for Colonic REctum Trial (SCORE) trial to 18% in the NORCCAP trial (Table 1).

As countries and large health-care systems consider moving from trial evidence about the efficacy of sigmoidoscopy to its implementation, it is important to understand the effect of the varying referral role in the writing of the editorial or the decision to submit the editorial for publication.

Notes
The author has no conflicts of interest to declare.

Affiliation of author: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD.
number needed to screen with colonoscopy to detect one person with APN was six for the U.K. criteria, eight for SCORE, and 10 for NORCCAP. Including the descending colon with the distal colon improved APN sensitivity by absolute amounts of 2% to 4% overall, by 5% to 8% for men aged 50–59 years, and by 8% to 9% for women aged 60–69 years. A large (≥10 mm) distal adenoma was the strongest independent predictor of APN.

The study by Castells and colleagues very nicely quantifies the trade-offs among the three sets of colonoscopy referral criteria between the proportion of advanced neoplasia detected and efficiency/resource utilization. These data may be used to inform countries and health-care systems about what to expect in terms of yield, efficiency, and resource allocation—information that may also be useful for comparing different CRC screening strategies. Reproducing the study findings in other large screening colonoscopy cohorts would strengthen these results, particularly for the age- and sex-specific subgroup analyses, and would determine the robustness of each set of referral criteria in different populations. The large screening colonoscopy datasets from Germany (11), Poland (12), and Austria (13) would be especially informative for these analyses.

One-time sigmoidoscopy detects most advanced colonic neoplasia; however, it is clear that using distal colonic findings alone in sigmoidoscopy screening—regardless of which criteria are used for colonoscopy referral—will miss most APN. Unfortunately, a breakdown is not provided of how much of the missed APN was advanced adenomas vs proximal CRC. Nevertheless, the high proportion of missed APN highlights the need for a way to quantify and stratify risk for advanced neoplasia among “average-risk” persons prior to consideration of any CRC screening. Effective risk stratification would help identify patient subgroups in which sigmoidoscopy would be particularly efficacious; it might also identify subgroups for which other screening tests may be warranted, either in addition to sigmoidoscopy (e.g., FIT) or in lieu of it (e.g., colonoscopy). Such a system has the potential to make CRC screening more efficient and could help increase the uptake of CRC screening to levels comparable to breast and cervical cancer screening.

References


4. Read TE, Read JD, Butterfly L.E. Importance of adenomas 5 mm or less in diameter that are detected by sigmoidoscopy. *New Engl J Med.* 1997;336(1):8–12.


**Funding**

Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine.

**Notes**

The author declares no conflicts of interest.

**Affiliations of author:** Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN; Regenstrief Institute, Inc, Indianapolis, IN; Center of Excellence for Implementing Evidence-Based Practice, Richard L. Roudebush VA Medical Center, Indianapolis, IN.